How should nausea be assessed in patients receiving chemotherapy?-Reference-Cited by-同舟云学术

How should nausea be assessed in patients receiving chemotherapy?

Published:1991-06 Issue:2 Volume:18 Page:85-93
ISSN:0305-7372
Container-title:Cancer Treatment Reviews
language:en
Short-container-title:Cancer Treatment Reviews

Author:

Kaye Stanley B.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Reference35 articles.

1. Double blind crossover study of the anti-emetic efficacy of high dose dexamethasone versus high dose metoclopramide;Aapro;J. Clin. Oncol.,1984

2. Antiemetic efficacy of high dose dexamethasone: randomized double blind, crossover study with a combination of dexamethasone, metoclopramide and diphenhydramine;Al-Idrissi;Br. J. Cancer,1988

3. Prevalence predictors and course of anticipatory nausea in women receiving adjuvant chemotherapy for breast cancer;Andrykowski;Cancer,1988

4. Lorazepam: a randomized double blind crossover study in patients receiving cytotoxic chemotherapy;Bishop;J. Clin. Oncol.,1984

5. Improved control of chemotherapy-induced emesis by the addition of dexamethasone to metoclopramide in patients resistant to metoclopramide;Bruera;Cancer Treat. Rep.,1983

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Best Supportive Care for Palliative Treatment;Head and Neck Cancer;2011

2. Chemotherapy-related nausea and vomiting - past reflections, present practice and future management;European Journal of Cancer Care;2004-03

3. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomized comparative trial of ondansetron versus placebo.;Journal of Clinical Oncology;1995-09

4. Progress in reducing nausea and emesis. Comparisons of ondansetron (zofran), granisetron (kytril), and tropisetron (navoban);Cancer;1995-08-01

5. A double-blind, randomised, crossover comparison of granisetron and ondansetron in 5-day fractionated chemotherapy: Assessment of efficacy, safety and patient preference;European Journal of Cancer;1994-01